Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.4515
-0.0033 (-0.73%)
At close: Apr 23, 2025, 4:00 PM
0.4520
+0.0005 (0.11%)
Pre-market: Apr 24, 2025, 4:32 AM EDT

Company Description

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.

The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition.

Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics, Inc.
Tenaya Therapeutics logo
Country United States
Founded 2016
IPO Date Jul 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 97
CEO Faraz Ali

Contact Details

Address:
171 Oyster Point Boulevard, Suite 500
South San Francisco, California 94080
United States
Phone 650 825 6990
Website tenayatherapeutics.com

Stock Details

Ticker Symbol TNYA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001858848
CUSIP Number 87990A106
ISIN Number US87990A1060
Employer ID 81-3789973
SIC Code 2836

Key Executives

Name Position
Faraz Ali M.B.A. Chief Executive Officer, Interim Principal Financial Officer and Director
Dr. Eric N. Olson Ph.D. Scientific Founder and Member of Scientific Advisory Board
Dr. Bruce R. Conklin M.D. Scientific Founder
Dr. Saptarsi Haldar M.D. Scientific Founder
Dr. Sheng Ding Ph.D. Scientific Founder
Dr. Benoit G. Bruneau Ph.D. Scientific Founder
Tomohiro Higa M.B.A. Senior Vice President of Finance and Interim Principal Accounting Officer
Dr. Kee-Hong Kim Ph.D. Chief Technology Officer
Michelle Corral Vice President of Investor Relationship and Corporate Communications
Jennifer Drimmer J.D. General Counsel and Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 18, 2025 8-K Current Report
Apr 17, 2025 ARS Filing
Apr 17, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2025 DEF 14A Other definitive proxy statements
Mar 31, 2025 EFFECT Notice of Effectiveness
Mar 28, 2025 8-K Current Report
Mar 21, 2025 S-3 Registration statement under Securities Act of 1933
Mar 10, 2025 144 Filing
Mar 10, 2025 144 Filing
Mar 10, 2025 10-K Annual Report